Leerink Partners Reiterates Market Perform Rating for Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR)‘s stock had its “market perform” rating reaffirmed by Leerink Partners in a report issued on Thursday, Marketbeat Ratings reports. They presently have a $105.00 price target on the medical research company’s stock. Leerink Partners’ target price points to a potential upside of 12.90% from the stock’s previous close.

ICLR has been the topic of a number of other research reports. Robert W. Baird set a $217.00 price objective on shares of Icon in a report on Friday, January 9th. UBS Group set a $220.00 price target on Icon in a research note on Friday, October 24th. Bank of America cut Icon from a “buy” rating to a “neutral” rating and set a $195.00 price objective for the company. in a research note on Monday, December 15th. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, Mizuho set a $216.00 price target on Icon in a report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $173.40.

Icon Stock Performance

Shares of ICLR stock opened at $93.00 on Thursday. The company’s fifty day moving average price is $175.93 and its 200-day moving average price is $174.94. The stock has a market cap of $7.51 billion, a PE ratio of 12.58, a price-to-earnings-growth ratio of 1.68 and a beta of 1.27. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon has a 12 month low of $66.57 and a 12 month high of $211.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Prosight Management LP increased its holdings in Icon by 0.5% in the 4th quarter. Prosight Management LP now owns 110,000 shares of the medical research company’s stock worth $20,044,000 after buying an additional 500 shares in the last quarter. Transamerica Financial Advisors LLC boosted its holdings in shares of Icon by 72.3% during the 4th quarter. Transamerica Financial Advisors LLC now owns 770 shares of the medical research company’s stock valued at $140,000 after acquiring an additional 323 shares during the last quarter. Quartz Partners LLC grew its stake in shares of Icon by 13.4% in the fourth quarter. Quartz Partners LLC now owns 18,104 shares of the medical research company’s stock worth $3,299,000 after acquiring an additional 2,145 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Icon by 14.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 242,504 shares of the medical research company’s stock valued at $44,189,000 after purchasing an additional 30,917 shares during the last quarter. Finally, Zuckerman Investment Group LLC lifted its position in Icon by 2.6% during the fourth quarter. Zuckerman Investment Group LLC now owns 155,643 shares of the medical research company’s stock valued at $28,361,000 after purchasing an additional 3,897 shares during the period. 95.61% of the stock is owned by institutional investors.

Icon News Roundup

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Some analyst support remains — Leerink Partners reaffirmed a “market perform” rating and a $105 price target, providing a floor for some investors. Leerink note
• Neutral Sentiment: ICON issued a timing update saying it is delaying release of Q4 and full?year 2025 earnings while the internal investigation continues — the announcement is procedural but keeps uncertainty elevated until results are filed. Company update
• Negative Sentiment: Multiple law firms have opened securities?fraud investigations and are soliciting shareholders after ICON disclosed possible revenue?recognition issues; that legal overhang amplifies downside risk and potential remediation costs. Glancy announcement
• Negative Sentiment: Market reaction has already been severe: the initial accounting?probe disclosure produced a large intraday share collapse and prompted additional plaintiff firms (Hagens Berman, Rosen, Block & Leviton, Frank R. Cruz, Ademi, Holzer & Holzer, Johnson Fistel, etc.) to launch or publicize investigations, increasing litigation risk and potential settlement exposure. Hagens Berman note
• Negative Sentiment: ICON pulled its 2025 outlook amid the probe and signaled potential revenue?recognition restatements, which elevates execution risk and clouds near?term earnings visibility — a key reason analysts and investors moved to cut exposure. Seeking Alpha

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.